Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAT2A | P31153 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497514 | 0.89 | MAPK1 (0.49) | MAPK1AURKAAURKBELANEMAPT | |
| SCHEMBL11826284 | 0.83 | MAPK1 (0.65) | MAPK1AURKAAURKBELANEMAPT | |
| SCHEMBL8956330 | 0.83 | MAPK1 (0.85) | MAPK1AURKAAURKBELANEMAPT | |
| SCHEMBL8410911 | 0.81 | MAPK1 (0.82) | MAPK1AURKAAURKBELANEMAPT | |
| SCHEMBL2319415 | 0.80 | BACE1 (0.58) | RAB9ASMN1; SMN2ALDH1A1HPGDKDM4E | |
| SCHEMBL28883104 | 0.80 | MAPK1 (0.61) | MAPK1AURKAAURKBELANEMAPT | |
| SCHEMBL29074153 | 0.80 | MAPK1 (0.61) | MAPK1AURKAAURKBELANEMAPT | |
| SCHEMBL11822896 | 0.80 | ALDH1A1 (0.61) | MAPK1AURKAAURKBELANEMAPT | |
| SCHEMBL29074154 | 0.79 | MAPK1 (0.60) | MAPK1AURKAAURKBELANEMAPT | |
| SCHEMBL28460515 | 0.76 | MAPK1 (0.57) | MAPK1AURKAAURKBELANEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116554211-A | Blue fluorescent material based on fluoroborobiquinoline complex, and preparation method and application thereof | 东南大学 | 2023-08-08 | — | — | CN | disclosed |
| EP-1999112-B1 | SUBSTITUTED 2-AMINO-4-PHENYL-DIHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-8399674-B2 | Quinolines | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399674-B2 | Quinolines | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399674-B2 | Quinolines | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120136018-A1 | QUINOLINES | KOLCZEWSKI SABINE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20120136018-A1 | QUINOLINES | KOLCZEWSKI SABINE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20120136018-A1 | QUINOLINES | KOLCZEWSKI SABINE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8106204-B2 | Substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2012-01-31 | — | — | US | disclosed |
| EP-2195296-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-20090088451-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| US-20090088451-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| US-20090088451-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| CN-101395137-A | Substituted 2-amino-4-phenyl-dhydroquinolines, method for the production thereof, use thereof as medicaments, and medicaments containing them | SANOFI AVENTIS (FR) | 2009-03-25 | — | — | CN | disclosed |
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1999112-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-D HYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | Sanofi-Aventis (FR) | 2008-12-10 | — | — | EP | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007107246-A2 | SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM | SANOFI-AVENTIS (DE) | 2007-09-27 | — | — | WO | disclosed |
| CN-1028754-C | process for preparing quinoline derivatives | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-06-07 | — | — | CN | disclosed |
| CN-1039416-A | Quinoline and preparation thereof and purposes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1990-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088451-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | MAPK1 2462/4885AURKA 2522/4885AURKB 2443/4885 |
| US-20120136018-A1 | QUINOLINES | HTR5A, HTR1A, HTR1E | MAPK1 2462/4885AURKA 2522/4885AURKB 2443/4885 |
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | MAPK1 2607/4885AURKA 4708/4885AURKB 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.